Кардиоваскулярный риск при ревматоидном артрите

1. <div><p>Попкова Т.В., Новикова Д.С., Насонов Е.Л. Атеросклероз при ревматических заболеваниях. В кн.: Ревматология: клинические рекомендации. M.: ГЭОТАР-Медиа, 2010; 678-702.</p><p>Peters M.J., Symmons D.P., McCarey D.W. et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other types of inflammatory arthritis — TASK FORCE «Cardiovascular risk management in RA». Ann Rheum Dis 2010; 69(2): 325-31.</p><p>Meune C., Touze E., Trinqurte L. et al. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analisis of cohort studies. Rheumatology 2009; 48(10): 1309-13.</p><p>Van Halm V.P., Peters M.J., Voskuyl A.E. et al. Rheumatoid arthritis versus type 2 diabetes as a risk factor for cardiovascular disease: a cross-sectional study. Ann Rheum Dis 2009; 68: 1395-400.</p><p>Maradit-Kremers H., Crowson C.S., Therneau T.M. et al. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients. A population- based cohort study. Arthr Rheum 2008; 58(8): 2268-74.</p><p>Goodson N.I., Willes N.J., Lunt N.C. Mortality on early inflammatory arthritis: cardiovascular mortality in seropositive patients. Arthr Rheum 2002; 46: 2010-9.</p><p>Gonzalez-Gay M.A., Gonzalez-Juanatey C., Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogen- esis. Semin Arthr Rheum 2005; 35: 8-17.</p><p>Gerli R., Bartoloni Bocci E., Sherer Y. et al. Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthri tis. Ann Rheum Dis 2008; 67: 724-5.</p><p>Lopez-Longo F.J., Oliver-Minarro D., de la Torre I. et al. Association between anticyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthr Rheum 2009; 61: 419-24.</p><p>Kumar N., Armstrong D.J. Cardiovascular disease — the silent killer in rheumatoid arthritis. Clin Med 2008; 8: 384-7.</p><p>Curtis J., John A., Baser O. et al. Frequency of lipid testing in patients with rheumatoid arthritis: a retrospective database analysis. Arthr Rheum 2009; 60(Suppl. 10): s516.</p><p>Российские рекомендации по диагностике и коррекции нарушений липидного обмена с целью профилактики и лечения атеросклероза. В сб.: Национальные клинические рекомендации. Под ред. Р.Г. Оганова. 2-е изд. М.: Силицея-Полиграф, 2009; 20-106.</p><p>Gazi I.F., Boumpas D.T., Mikhailidis D.P. et al. Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins. Clin Exp Rheum 2007; 25: 102-11.</p><p>Попкова Т.В., Новикова Д.С., Новиков А.А. и др. Роль нарушений в системе транспорта холестерина крови в развитии атеросклероза при ревматоидном артрите. Науч.-практич. ревматол. 2007; 5: 4-10.</p><p>Попкова Т.В., Новикова Д.С., Герасимова Е.В. и др. Значение факторов риска в прогнозировании клинических проявлений атеросклероза при СКВ и РА. Сб. матер. V съезда ревматологов России. М., 2009; 91.</p><p>Bisoendial R., Stroes E., Kastelein J., Tak P. Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins. Nat Rev Rheum 2010; doi: 10.1038/nrrheum.2009.277</p><p>Nurmohamed M., Dijkmans B. Dyslipidemia, statins and rheumatoid arthritis. Ann Rheum Dis 2009; 68: 453-5.</p><p>Nielen M.J., van Halm V.P., Nurmohamed M.T. et al. Rheumatoid arthritis is preceded by a preclinical phase, characterized by increased C-reactive protein levels and a more atherogenic lipid profile. Arthr Rheum 2003; 48: 344.</p><p>Van Halm V.P., Nielen M.J., Nurmohamed M.T. et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 2006; 3: 1-5.</p><p>Myasoedova E., Gabriel S. Cardiovascular disease in rheumatoid arthritis: a step forward. Curr Opin Rheumatol 2010; 22: 342-7.</p><p>Giles J.T., Post W., Blumenthal R.S. et al. Therapy insight: managing cardiovascular risk in patients with rheumatoid arthritis. Nat Clin Pract Rheum 2006; 6: 320-9.</p><p>Papadopoulos N.G., Alamanos Y.,Voulgari P.V. et al. Does cigarette smoking influence disease expression, activity and severity in early rheumatoid arthritis patients? Clin Exp Rheum 2005; 23: 861-6.</p><p>Jick S.S., Choi H., Li L. Hyperlipidemia, statin use and the risk of developing rheumatoid arthritis. Ann Rheum Dis 2009; 68(4): 546-51.</p><p>Choi E., Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 2009; 68: 460-9.</p><p>Sattar N., Crompton P., Cherry L. Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study. Arthr Rheum 2007; 56: 831-9.</p><p>Khovidhunkit W., Kim M.S., Memon R.A. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004; 45: 1169-96.</p><p>Burger D., Dayer J.M. High-density lipoprotein-associated apolipoprotein A-1: the missing link between infection and chronic inflammation? Autoimmun Rev 2002; 1: 111-7.</p><p>Navab M., Berliner J.A., Subbanagounder G. et al. HDL and inflammatory response induced by LDL-derived oxidized phospholipids. Arteriol Thromb Vasc Biol 2001; 21: 481-8.</p><p>McMahon M., Grossman J., FitzGerald J. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthr Rheum 2006; 54: 2541-9.</p><p>Lourida E.S., Georgiadis A.N., Papavasiliou E.C. et al. Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized low-density lipoprotein and exhibit decreased activity of the lipoprotein-associated phospholipase A2. Arthr Res Ther 2007; 9: 19.</p><p>Ananth L., Prete P.E., Kashyap M.L. et al. Apolipoproteins A-I and B and cholesterol in synovial fluid of patients with rheumatoid arthritis. Metabolism 1993; 42: 803-6.</p><p>Pearson T.A., Mensah G.A., Alexander R.W. et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.</p><p>Montecucco F., Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology 2009; 48: 11-22.</p><p>Насонов Е.Л., Панюгова Е.В., Александрова Е.Н. С-реактивный белок — маркер воспаления при атеросклерозе (новые данные). Кардиология 2002; 7: 53-62.</p><p>Goodson N.J., Symmons D.P., Scott D.G. et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup of primary care-based inception cohort. Arthr Rheum 2005; 52: 2293-9.</p><p>Poole C.D., Conway P., Currie C.J. An evaluation of the association between C- reactive protein, the change in C-reactive protein over one year, and all-cause mortality in chronic immune-mediated inflammatory disease managed in UK general practice. Rheumatology 2009; 48: 78-82.</p><p>Dursunoglu D., Ervengul H., Polat B. et al. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheum Int 2005; 25: 241-5.</p><p>Munro R., Morrison E., McDonald A.G. et al. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis 1997; 56: 374-7.</p><p>Park Y.B., Lee S.K., Suh C.H. et al. Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 1999; 26: 1701-4.</p><p>Yoo W.H. Dyslipoproteinemia in patients with active rheumatoid arthritis: effects of disease activity, sex, and menopausal status on lipid profiles. J Rheumatol 2004; 31: 1746-53.</p><p>Hulthe J., Fogerberg B. Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR study). Arterioscler Thromb Vasc Biol 2002; 22: 1162-7.</p><p>Hashizume M., Yoshida H., Koike N. et al. IL-6 reduces blood lipid levels via up- regulation of VLDR receptors. Arthr Rheum 2009; 60(Suppl. 10): s11.</p><p>Woods A., Brull D.J., Humphries S.E. et al. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J 2000; 21: 1574-83.</p><p>Popa C., Netea M.G., Radstake T.R. et al. Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis. Ann Rheum Dis 2005; 64: 303-5.</p><p>Genest J., Jenner J.L., McNamara J.R. et al. Prevalence of lipoprotein (a) excess in coronary artery disease. Am J Cardiol 1991; 67: 1039-45.</p><p>Seriolo B., Accardo S., Fasciolo D. et al. Lipoproteins, anticardiolipin antibodies and thrombotic events in rheumatoid arthritis. Clin Exp Rheum 1996; 14: 593-9.</p><p>Burchard E.G., Ziv E., Coyle N. et al. The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med 2003; 348: 1170-5.</p><p>Cisternas M., Gutierrez M.A., Klassen J. et al. Cardiovascular risk factors in Chilean patients with rheumatoid arthritis. J Rheumatol 2002; 29: 1619-22.</p><p>Solomon D.H., Karlson E.W., Rimm E.B. et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 11: 1303-7.</p><p>Fan J., Watanabe T. Inflammatory reactions in the pathogenesis of atherosclerosis. J Atheroscler Thromb 2003; 10: 63-71.</p><p>Dahlen G.H., Guyton J.R., Altar M. et al. Association of levels of lipoprotein (a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1998; 74: 758-65.</p><p>Lee Y.H., Choi S.J., Ji J.D. et al. Lipiprotein (a) and lipids in relation to inflammatory in rheumatoid arthritis. Clin Rheumatol 2000; 19: 324-5.</p><p>Cesur M., Ozbalkan Z., Temel M.A. et al. Ethnicity may be a reason for lipid changes and high Lp (a) levels in rheumatoid arthritis. Clin Rheumatol 2007; 26: 355-61.</p><p>Asanuma Y.U., Kawai S., Aoshima H. et al. Serum lipoprotein (a) and apolipoprotein (a) phenotypes in patients with rheumatoid arthritis. Arthr Rheum 1999; 42: 443-7.</p><p>Garsia-Gomez С., Nolla J., Valverde J. et al. Conventional lipid profile and lipoprotein (a) concentration in treated patients with rheumatoid arthritis. J Rheumatol 2009; 36: 1365-70.</p><p>Marardit-Kremers H., Nicola P.J., Crowson C.S. et al. Cardiovascular death in rheumatoid arthritis. A population-based study. Arthr Rheum 2005; 52: 722-32.</p><p>Naranjo A., Sokka T., Descalzo M.A. et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthr Res Ther 2008; 10: R30.</p><p>Semb G., Walldius A., Aastveit R. et al. Lipoprotein components are not assotiated with miocardial infarction or stroke in RA. Arthr Rheum 2009; 60 (Suppl. 10): s524.</p><p>Toms T.E., Panoulas V.F., Douglas K.M. et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial under treatment of lipid associated cardiovascular risk? Ann Rheum Dis 2009; Oct 23 [Epub. ahead of print].</p><p>Edwards C.J., Fisher D., van Staa T. Myocardial infarction in rheumatoid arthritis: the effects of traditional risk factors, antihypertensive and lipid-lowering medication. Arthr Rheum 2007; 58(Suppl. 9): 420.</p><p>Carroll L., Frazer I.H., Turner M. et al. Receptor for advanced glycation end products Glycine 82 Serine polymorphism and risk of cardiovascular events in rheumatoid arthritis. Arthr Res Ther 2007; 9: R39.</p><p>Kumar P., Khan F., Kennedy G. et al. Effect of rosuvaststin on surrogate markers of cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67(Suppl. II): 172.</p><p>Semb A.P., Holme I., Kvien T.K. Intensive lipid lowering in patients with rheumatoid arthritis. Ann Rheum Dis 2009; 68(Suppl. 3): 410.</p><p>Насонов Е.Л. Перспективы применения статинов в ревматологии. Рус. мед. журн. 2003; 11: 1273-6.</p><p>Abeles A.M., Pillinger M. Statins as antiinfammatory and immunomodulatory agents. A future in rheumatologic therapy? Arthr Rheum 2006; 54: 393-407.</p><p>Ширинский И.В., Козлов В.А., Ширинский В.С. Использование статинов — новый подход к терапии аутоиммунных заболеваний. Вестн. РАМН 2009; 2: 25-32.</p><p>Никитина Н.М., Ребров А.П. Место статинов в комплексной терапии больных ревматоидным артритом. Болезни сердца и сосудов 2009; 4: 58-61.</p><p>Sarantopoulos A.A., Skendros P., Tselios K. et al. Study of immunomodulating effects of statins in rheumatoid arthritis patients with accelerated atherosclerosis. Ann Rheum Dis 2008; 67(Suppl. II): 205.</p><p>Yokota K., Ishibashi T., Asanuma Y. et al. Simvastatin inhibits production of pentraxin 3 and momocyte chemoattractant protein-1 in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67(Suppl. II): 207.</p><p>Nah S., Won H., Shin B. et al. HMG-KoA reductase inhibitors (statins) inhibits the expansion of CD4+CD25+ regulatory T cell. Ann Rheum Dis 2008; 67(Suppl. II): 454.</p><p>Lazzerini P.E., Lorenzini S., Selvi E. et al. Simvastatin inhibits cytokine production and nuclear factor-kB activation in interleukin 1β-stimulated synoviocytes from rheumatoid arthritis patients. Clin Exp Rheum 2007; 25: 696-700.</p><p>Rosenson R.S., Tangney C.C. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998; 279: 1643-9.</p><p>Pucetti L., Pascui A.L., Auteri A. et al. Mechanisms for antiplatelet action of statins. Curr Drug Targets Cardiovasc Haematol Disord 2004; 5: 121-6.</p><p>Wada H., Mori Y., Kaneko T. et al. Hypercoagulable state in patients with hypercholesterolemia: effects of pravastatin. Clin Ther 1992; 14: 829-34.</p><p>Avellone G., Di Garbo V., Cordova R. et al. Changes induced by pravastatin treatment on hemostatic and fibrinolytic patterns in patients with type IIB hyperlipoproteinemia. Curr Ther Res Clin Exp 1994; 55: 1335-9.</p><p>Kimura T., Mogi C., Tomura H. et al. Induction of scavenger receptor class B type I is critical for simvastatin enhancement of high-density lipoprotein-induced antiinflammatory actions in endothelial cells. J Immunol 2008; 15(181(10)): 7332-40.</p><p>Brugaletta S., Biasucci L.M., Pinnelli M. et al. Novel anti-inflammatory effect of statins: reduction of CD4+CD28null T lymphocyte frequency in patients with unstable angina. Heart 2006; 92: 249-50.</p><p>Yokota K., Mioyoshi F., Myazaki K. et al. High concentration simvastatin induces apoptosis in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Rheumatol 2008; 35: 193-200.</p><p>Leung B.P., Sattar N., Crilly A. et al. A novel anti-inflammatory tole for simvastatin in inflammatory arthritis. J Immunol 2003; 170: 1524-30.</p><p>Yamagata T., Kinoshita K., Nozaki Y. et al. Effects of pravastatin in murine collagen-induced arthritis. Rheumatol Int 2007; 27(7): 631-9.</p><p>Charles-Schoeman C., Banquerigo M.L., Hama S. et al. Treatment with an apolipoprotein A-1 mimetic peptide in combination with pravastatin inhibits collagen-induced arthritis. Clin Immunol 2008; 127: 234-44.</p><p>Palmer G., Chobaz V., Talabot-Ayer D. et al. Assessment of the efficacy of different statins in murine collagen-induced arthritis. Arthr Rheum 2004; 50(12): 4051-9.</p><p>Amital H., Chodick G., Shalem Y., Shalev V. HMG-CoA reductase inhibitors (statins) provides primary prevention for rheumatoid arthritis. Arthr Rheum 2009; 60(Suppl. 10): s438.</p><p>Gunnarsson M., Wedren S., Klareskog L. Use of statins and risk of developing rheumatoid arthritis — results from the EIRA study group. Ann Rheum Dis 2009; 68(Suppl. 3): 529.</p><p>Kanda H., Hamasaki K., Kubo K. et al. Antiinflammatory effect of simvastatin in patients with rheumatoid arthritis. J Rheumatol 2002; 29(9): 2024-6.</p><p>Abud-Mendoza C., de la Fuente H., Cuevas-Orta E. Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus 2003; 12(8): 607-11.</p><p>McCarey D.W., McInnes I.B., Madhok R. et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): doubleblind, randomized placebo-controlled trial. Lancet 2004; 363: 2015-21.</p><p>Shirinsky I.V., Zheltova O.I., Solovyeva N.Y. et al. Changes in disease activity, cytokine production, and proliferation of peripheral blood mononuclear cells in patients with rheumatoid arthritis after sim- vastatin treatment. Scand J Rheumatol 2009; 38(1): 23-7.</p><p>Okamoto H., Koizumi K., Kamitsuji S. et al. Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. J Rheumatol 2007; 34: 964-8.</p><p>Kanda H., Yokota K., Kohno C. et al. Effects of low-dosage simvastatin on rheumatoid arthritis through reduction of Th1/Th2 and CD4/CD8 ratios. Mod Rheum 2007; 17(5): 364-8.</p><p>Charles-Schoeman C., Khanna D., Furst D.E. et al. Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: A Pilot Study. J Rheumatol 2007; 7: 1-6.</p><p>Hermann F., Forster A., Chenevard R. et al. Simvastatin improves endothelial function in patients with rheumatoid arthritis. JACC 2005; 45: 461-4.</p><p>Tikiz C., Utuk O., Pirildar T. et al. Effects of angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis. J Rheumatol 2005; 32: 2095-101.</p><p>Van Doornum S., McColl G., Wicks I.P. Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Ann Rheum Dis 2004; 63: 1571-5.</p><p>Никитина Н.М., Ребров А.П. Применение аторвастатина у больных ревматоидным артритом с гиперлипидемией. Кардиология 2009; 9: 21-6.</p><p>Mäki-Petäjä K.M., Booth A.D., Hall F.C. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. JACC 2007; 9: 852-8.</p><p>Тутунов В.С., Попкова Т.В., Новикова Д.С. и др. Сравнительная оценка противовоспалительного действия аторвастатина при ишемической болезни сердца и ревматоидном артрите. Кардиология 2008; 9: 4-8.</p><p>Попкова Т.В., Алекберова З.С., Александрова Е.Н., Насонов Е.Л. Опыт применения ловастатина (Медостатин®) у пациентов с системной красной волчанкой и ревматоидным артритом. Рус. мед. журн. 2005; 7: 400-2.</p><p>Lodi S., Evans S.J., Egger P. Is there an antiinflammatory effect of statins in rheumatoid arthritis? Analysis of a large routinely collected claims database. Br J Clin Pharmacol 2010; 69(1): 85-94.</p><p>Кардиология: национальное руководство. Под ред. Ю.Н. Беленкова, Р.Г. Оганова. М.: ГЭОТАР-Медиа, 2007; 1232 с.</p><p>Funk L., Chen J., Downey K. et al. Bone protective effect of simvastatin in experimental arthritis. J Rheumatol 2008; 35: 1083-91.</p><p>Kim J., Lee E., Hong Y. et al. Atorvastatin and simvastatin inhibits osteoclastogenesis by decreasing the expression of receptor activator of NFkB ligand (RANKL) in rheumatoid arthritis fibroblast-like synoviocyte. Arthr Rheum 2009; 60(Suppl. 10): s616.</p><p>Cусеков А.В., Рожкова Т.А., Трипотень М.И. и др. Рандомизированное исследование Фарватер: часть II. Эффект аторвастатина на функцию эндотелия, растяжимость и жесткость сосудистой стенки. Кардиоваск. тер. профилакт. 2007; 6(3): 68-75.</p><p>Ljung L., Leirisalo-Repo M., Yki- Järvinen H. et al. Improvement of cardiovascular risk markers with atorvastatin treatment in rheumatoid arthritis. Arthr Rheum 2009; 60(Suppl. 10): s159.</p><p>Graf J. Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis. 2009; www.plosone.org</p><p>Ridker P.M., Danielson E., Fonseca F.A. et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373: 1175-82.</p><p>Ridker P.M., Solomon D.H. Should patients with rheumatoid arthritis receive statin therapy? Arthr Rheum 2009; 60: 1205-9.</p><p>Bansback N., Ara R., Ward S. Statin therapy in rheumatoid arthritis: a cost-effectiveness and value-of-information analysis. Pharmacoeconomics 2009; 27: 5-37.</p><p>Попкова Т.В., Новикова Д.С., Новиков А.А. и др. Роль системного воспаления в развитии сердечно-сосудистых осложнений при ревматоидном артрите. Науч.-практич. ревматол. 2009; 3(Прил.): 61-9.</p><p>Curtis J., John A., Baser O. et al. Quantification of dyslipidemia among patients with rheumatoid arthritis and changes with initiation of anti-TNF therapy: a retrospective database analysis. Arthr Rheum 2009; 60(Suppl. 10): s597.</p><p>Saiki O., Takao R., Naruse Y. et al. Infliximab but not methotrexate induces extra-high levels of VLDL-triglyceride in patients with rheumatoid arthritis. J Rheumatol 2007; 34(10): 1997-2004.</p><p>Mohaupt M.G., Karas R.H., Babiychuk E.B. Association between statin-associated myopathy and skeletal muscle damage. CMAJ 2009; 7(181(1 — 2)): E11-Е18.</p><p>Joy T.R., Hegele R.A. Narrative review: statin-related myopathy. Ann Intern Med 2009; 16: 858-68.</p><p>Mosshammer D., Lorenz G., Meznaric S. Statin use and its association with musculoskeletal symptoms — a cross-sectional study in primary care settings. Fam Pract 2009; 26(2): 88-95.</p><p>McClure D.L., Valuck R.J., Glanz M. Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population. J Clin Epidemiol 2007; 60: 812-8.</p><p>Gaist D., Rodriguez L.A., Huerta G. et al. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 2001; 12: 565- 9.</p><p>Molokhia M., McKeigue P., Curcin V. Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991-2006. 2008, PLoS ONE, 3, www.plosone.org</p><p>Scott D., Blizzard L., Fell J. Statin therapy, muscle function and falls risk in community-dwelling older adults. Quart J Med 2009; 102(9): 625-33.</p><p>Lee P., Greenfield J.R., Campbell L.V. Vitamin D insufficiency — a novel mechanism of statin-induced myalgia? Clin Endocrinol 2009; 71(1): 154-5.</p><p>Ghatak A., Faheem O., Thompson P.D. The genetics of statin-induced myopathy. Atherosclerosis 2009 [Epub. ahead of print].</p><p>Затейщиков Д.А. Проблемы безопасности статинов. Фарматека 2005; 8(103): 75-8.</p><p>Nishiguchi T., Akiyoshi T., Anami S. Synergistic action of statins and nitrogen- containing bisphosphonates in the development of rhabdomyolysis in L6 rat skeletal myoblasts. J Pharm Pharmacol 2009; 61(6): 781-8.</p><p>Backes J.M., Howard P.A., Ruisinger J.F. et al. Does simvastatin cause more myotoxicity compared with other statins? Ann Pharmacother 2009; 43(12): 2012-20.</p><p>Ara R., Pandor A., Stevens J. et al. Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation. Health Technol Assess 2009; 13(34): 1 -118.</p><p>Kostapanos M.S., Milionis H.J., Elisaf M.S. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am J Cardiovasc Drugs 2010; 10(1): 11-28.</p><p>Grable-Esposito P., Katzberg H.D., Greenberg S.A. et al. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010; 41(2): 185-90.</p><p>Noël B. Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol 2007; 21(1): 17-24.</p><p>Suchak R., Benson K., Swale V. Statin-induced Ro/SSa-positive subacute cutaneous lupus erythematosus. Clin Exp Dermatol 2007; 32(5): 589-91.</p><p>Asbach P., Paetsch I., Stawowy P. et al. Statin-associated focal myositis. Int J Cardiol 2009; 133(1): 33-4.</p><p>Inhoff O., Peitsch W.K., Paredes B.E. et al. Simvastatin-induced amyopathic dermatomyositis. Br J Dermatol 2009; 161(1): 206-8.</p><p>Rasch A., Schimmer M., Sander C.A. Simvastatin-induced dermatomyositis. Hautarzt 2009; 60(6): 489-93.</p><p>Zuech P., Pauwels C., Duthoit C. et al. Pravastatin-induced dermatomyositis. Rev Med Interne 2005; 26(11): 897-902.</p><p>Thual N., Penven K., Chevallier G. et al. Fluvastatin-induced dermatomyositis. Ann Dermat Vener 2005; 132(12 Pt 1): 996-9.</p><p>Sailler L., Pereira C., Bagheri A. et al. Increased exposure to statins in patients developing chronic muscle diseases: a 2- year retrospective study. Ann Rheum Dis 2008; 67(5): 614-9.</p><p>Toms T.E., Smith J.P., Panoulas V.F. Prevalence of risk factors for statin-induced myopathy in rheumatoid arthritis patients. Musculoskeletal Care 2009 [Epub. ahead of print].</p><p>Marie I., Delafenetre H., Massy N. et al. Tendinous disorders attributed to statins: a study on ninety-six spontaneous reports in the period 1990-2005 and review of the literature. Arthr Rheum 2008; 59(3): 367-72.</p></div><br />